BDI Pharma Inc., a national distributor of biotech therapies, has launched an animal health division to focus on the biopharmaceutical needs of veterinary professionals.
The launch of the new division, 4legPharma, has been in the making for some time, according to Angela Phillips, director of animal health. BDI Pharma has been serving the veterinary community since 1995 and has experienced significant growth within this sector for extralabel use, she said.
“As the animal health division of BDI Pharma, 4legPharma is backed by over 15 years of experience in handling urgent need, critical care pharmaceutical products,” Phillips said. “We are uniquely positioned to offer veterinary specialists the best of both animal drugs as well as human therapies for extralabel use to treat pets suffering from the same chronic, life-threatening conditions that affect humans.”
4legPharma gives the appropriate sales channel for veterinarians, she added.
Current product categories offered by 4legPharma: antibiotics, chemotherapy, generic specialty drugs, human intravenous immunoglobulin (IVIG) and albumin and veterinary pharmaceuticals. 4legPharma plans to expand the product line down the road.
Although BDI Pharma just announced the new division earlier this week, the company has had a tremendous response, Phillips said. The division’s corresponding website, www.4legpharma.com, had about 4,100 hits within the first two days.
Phillips noted that BDI Pharma is recognized as an ADR, or Authorized Distributor of Record, for all of the manufacturers it represents. ADR’s are the first to receive important product warnings and recall information from the manufacturers, which is shared with customers in a timely manner, according to the company.
As a division of BDI Pharma, 4legPharma will retain the ADR status. The status is important to the more discriminative veterinarians, she said.
4legPharma will exhibit for the first time at NAVC, set to take place Jan. 15-19 in Orlando, Fla.
BDI Pharma and its animal health division are based in Columbia, S.C.